Conference MDAngle offers personal perspectives from conference attendees, showcasing their anticipation, quick takeaways, and insights into how the presented research will affect their patients. The ...
Please provide your email address to receive an email when new articles are posted on . Top-line results of a phase 2 clinical trial for an adipose-derived autologous mesenchymal stem cell therapy to ...
– Enrollment Completed for Both Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis; Top-Line Data Expected End of 2026 – – Additional Data from Phase 2 CALLIPER Trial in ...
Dr Pavan Bhargava recently returned from the 2025 AAN Annual Meeting, where key updates in relapsing-remitting multiple sclerosis (RRMS) were highlighted. He noted the introduction of the 2024 ...
Secondary progressive multiple sclerosis (SPMS) usually develops after years of relapsing-remitting multiple sclerosis (RRMS) and leads to steadily worsening symptoms and disability over time. SPMS ...
A registry study led by the University of Oulu examined the early-stage treatment of relapsing-remitting multiple sclerosis (MS) in Finland between 2013 and 2022. According to the study, MS treatment ...
medwireNews: The DECIDE study shows that 4-weekly daclizumab high-yield process (HYP) reduces disease activity in patients with relapsing–remitting multiple sclerosis (MS) more effectively than weekly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results